Recent Updates
Recently added Catalysts
ECOR Positive Sentiment

electroCore to Participate in Upcoming Investor Conferences

Key Takeaway: electroCore, Inc. announced its participation in two upcoming investor conferences, including the Needham 11th Annual Virtual MedTech and Diagnostics Conference and the Canaccord Genuity 46th Annual Growth Conference. Management will host presentations and one-on-one meetings to engage with investors. This participation highlights the company's focus on investor relations and its innovative bioelectronic technologies.
Price reaction · baseline $6.085 (2026-07-31 close) · hit pre-market · 1 other ECOR headline(s) in the window, move may be shared
day 0 close
+0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in two significant investor conferences.
  • Opportunity for one-on-one meetings with management.
  • Showcases the company's commitment to engaging with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
GammaCore
Phase 2 · Chronic Cluster Headache

Full Press Release Details

ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences:
• Needham 11th Annual Virtual MedTech and Diagnostics Conference, taking place virtually on Tuesday, August 11, 2026. Management will host one-on-one meetings virtually.
• Canaccord Genuity 46th Annual Growth Conference, taking place in Boston, Massachusetts, on Tuesday, August 11, and Wednesday, August 12, 2026, at the InterContinental Boston. Management will present on Tuesday, August 11, at 4:30 p.m. ET and will host one-on-one meetings on Wednesday, August 12.
Investors who wish to request a meeting should contact their sales representative at the sponsoring firms or reach out to electroCore Investor Relations at investors@electrocore.com.
About electroCore, Inc. electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.

Contact: ECOR Investor Relations (973) 302-9253 investors@electrocore.com

Frequently Asked Questions

What conferences will electroCore participate in?

electroCore will participate in the Needham 11th Annual Virtual MedTech Conference and the Canaccord Genuity 46th Annual Growth Conference.

When will electroCore present at the conferences?

electroCore will present on August 11, 2026, at the Canaccord Genuity conference at 4:30 p.m. ET.

How can investors request a meeting with electroCore?

Investors can request a meeting by contacting their sales representative or reaching out to electroCore Investor Relations.

What products does electroCore offer?

electroCore offers gammaCore and Quell, which are non-invasive devices for treating chronic pain.

Last updated: Aug 3, 2026